350 Technology Drive
Suite 421
Pittsburgh, PA 15219
United States
412 763 3350
https://www.neubasetherapeutics.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 37
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Todd P. Branning | Interim CEO, CFO & Secretary | 396,3k | N/A | 1970 |
Dr. Dietrich A. Stephan Ph.D. | Founder, President & Director | 775,62k | N/A | 1970 |
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 7, Kompensation: 8.